Innate Pharma Accounts Payable

Innate Pharma (IPHA) currently reports a accounts payable of $5.4M as of June 2026. That compares with $4.6M in the prior-year period — up 19.3% year over year. Use the charts on this page to explore Innate Pharma's accounts payable history and peer comparisons.

Innate Pharma's accounts payable increased from $4.6M to $5.4M — a 19.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma reported $5.4M in accounts payable as of June 2026. That compares with $4.6M in the prior-year period — up 19.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $5.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.

Innate Pharma is classified in the Healthcare sector. On accounts payable, it currently shows $5.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPHA with unrelated industries.